A Study of OV101 in Individuals With Angelman Syndrome (AS)
Study sponsor: Ovid Therapeutics Inc. · OVID
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-11-02Actual
Enrollment · participants104Actual
Source updated2024-01-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.